Vir’s Covid-19 antibody is finally going to the clinic
Vir Biotechnology has seen its share price rise nearly five-fold since the start of the year thanks to its potential to develop treatments for the novel coronavirus. But while rivals Regeneron Pharmaceuticals and Eli Lilly quickly took their therapies into the clinic, Vir has spent the last few months honing a pair of antibodies for Covid-19 and promising to start trials as soon as possible.
Yesterday, the company committed to a hard timeline, plotting to start a Phase 2/3 study by the end of this month. Because it’s a few months behind, the stakes for Vir are a little odd. If Regeneron and Lilly’s antibodies work, there might be little demand for Vir’s third-place offering. And if they fail, it becomes considerably unlikely that Vir would succeed.
The best-case scenario is that Vir’s antibody, which is derived from patients who have recovered from the SARS coronavirus, proves to be better than its competitors. But because Vir is taking extra time to start its study, we won’t have data until months after its competitors.
Yesterday, the company committed to a hard timeline, plotting to start a Phase 2/3 study by the end of this month. Because it’s a few months behind, the stakes for Vir are a little odd. If Regeneron and Lilly’s antibodies work, there might be little demand for Vir’s third-place offering. And if they fail, it becomes considerably unlikely that Vir would succeed.
The best-case scenario is that Vir’s antibody, which is derived from patients who have recovered from the SARS coronavirus, proves to be better than its competitors. But because Vir is taking extra time to start its study, we won’t have data until months after its competitors.
.png)
No hay comentarios:
Publicar un comentario